The major Novosibirsk pharmaceutical manufacturer "Obnovlenie" (Renewal) plans to launch two new production facilities by 2027. This will ensure the localization of popular drugs such as diclofenac, ketorolac, ketoprofen, drotaverine, and pyridoxine. TASS reports this, citing the company.
As previously reported by RBC Novosibirsk, at the beginning of the year, the pharmaceutical company was granted a permit for the second phase of construction works to build Pharmaceutical Production Facility No. 7, an energy building, a warehouse, an administrative building, and garages. The construction site is located on Stantsionnaya Street in the Leninsky District of the city. The permit is valid until March 3, 2025.
The executive director of the pharmaceutical company Renewal ("PFC Obnovlenie"), Vladimir Grechkinn, told RBC Novosibirsk that the total cost of the project amounts to 3 billion rubles.
"Production Line No. 7 is being built for the production of solid dosage forms: capsules, tablets, and effervescent tablets. Importantly, the new site will provide the opportunity to create backup production capacities for future medications. The plant's production potential will increase by 100 million packages of drugs per year," Grechkinn explained.
Renewal ("Pharmaceutical Production Company Obnovlenie") is one of the largest Russian manufacturers of medicines, with its production and research complex located in Novosibirsk and the Suzun urban-type settlement. Since 1997, the company has been engaged in the development and production of pharmaceuticals.
Source: www.nsk.rbc.ru
